Arvinder Pal Walia
Psychiatry · Austin, TXNPI 1427163617
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,003,217 of the $2,540,630 with a category attached, or 78.8%. 28 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 28.6% of the total. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4,186 payments — averaging $606.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$728K
- AbbVie$681K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$501K
- Otsuka America Pharmaceutical, Inc.$265K
- Axsome Therapeutics, Inc.$121K
- Alkermes, Inc.$93K
- plus $152K from 22 others
What the payments were for
- Consulting fees$121,8305%
- Speaking & faculty fees$2,003,21779%
- Travel & lodging$344,13414%
- Food & beverage$71,3283%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 695 | $727,697 |
| AbbVie(2 entities) | 1,241 | $681,120 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 697 | $500,778 |
| Otsuka America Pharmaceutical, Inc. | 573 | $264,875 |
| Axsome Therapeutics, Inc. | 181 | $120,547 |
| Alkermes, Inc. | 248 | $93,232 |
| Vanda Pharmaceuticals Inc. | 108 | $49,664 |
| E.r. Squibb & Sons, L.L.C. | 64 | $40,061 |
| Johnson & Johnson | 59 | $23,583 |
| Takeda Pharmaceuticals U.S.A., Inc. | 97 | $22,231 |
| Sunovion Pharmaceuticals Inc. | 59 | $6,952 |
| Eisai Inc. | 14 | $4,588 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $1,631 |
| Jazz Pharmaceuticals Inc. | 13 | $1,350 |
| Corium, LLC | 52 | $803 |
| Lundbeck LLC | 27 | $422 |
| Supernus Pharmaceuticals, Inc. | 10 | $300 |
| Neurocrine Biosciences, Inc. | 10 | $211 |
| Idorsia Pharmaceuticals US Inc | 10 | $131 |
| Tris Pharma Inc | 7 | $127 |
| Teleflex LLC | 1 | $105 |
| Ironshore Pharmaceuticals Inc. | 4 | $67 |
| Bausch Health US, LLC | 3 | $62 |
| SRS Medical Systems, Inc. | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 2 | $23 |
| Shire North American Group Inc | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,540,630 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 23 | $259,034 |
| TrintellixVortioxetine Hydrobromide | 35 | $25,512 |
| Aripiprazole | 57 | $4,141 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $1,962 |
| Trazodone Hcl | 58 | $1,617 |
| Olanzapine | 37 | $1,189 |
| Duloxetine Hcl | 30 | $877 |
| Lurasidone Hcl | 15 | $766 |
| Clozapine | 12 | $747 |
| Lithium Carbonate ErLithium Carbonate | 39 | $648 |
| Lamotrigine | 50 | $553 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $524 |
| Paroxetine Hcl | 36 | $486 |
| Bupropion XlBupropion Hcl | 26 | $459 |
| Bupropion Hcl | 12 | $439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $727,697 | $259,03423 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $22,231 | $25,51235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Austin
- Charles NemeroffAustin$429K
- Divyansu PatelAustin$50K
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.